News

Outcomes in relapsed/refractory myeloma remain poor, and novel therapy approaches are necessary, according to findings from a study published in Clinical Lymphoma, Myeloma & Leukemia.

Results from a recent study indicated that mantle cell lymphoma patients have higher relative risks of respiratory, blood, and infectious disease compared to healthy comparators and that late effects varied very little by treatment with or...

Mantle cell lymphoma with optic nerve involvement is a rare oncologic process, with whole-brain radiation therapy conventionally utilized as a palliative treatment.

General physicians and other providers are progressively referring patients requiring cerumen disimpaction to otolaryngologist physicians and permitting advanced practice providers to perform these procedures, suggesting a shift in landscape...

Nursing model intervention established on Rosenthal effect may improve the self-efficacy and meaning of life in patients with non-small cell lung cancer, and diminish the negative emotions and self-burden.

Findings from a recent cross-sectional study of national cancer care expenditures and cancer mortality rates across 22 high-income countries indicate that although the cancer mortality rate in the US was lower than the median, the US spent...

Amy McKee, MD, Head of Regulatory Oncology, Parexel, and Alex Gee, Senior Director, Pricing and Market Access, Parexel, provided information about recent advancements in evidence needed to support oncology drug development and shared insights...

In a recent press release, the top global life sciences company, Labcorp, announced its decision from its Board of Directors to move forward with a spinoff of the company’s wholly owned Clinical Development business to shareholders of Labcorp...

In a recent press release, the Centers for Medicare and Medicaid Services (CMS) announced that the average basic monthly premium for standard Medicare Part D coverage is predicted to be nearly $31.50 in 2023, a reduction of 1.8% from $32.08...

Findings from a recent study suggest that neither PD-1 nor its ligands represent relevant targets for mantle cell lymphoma treatment, however, age may impact the efficiency of immune checkpoint inhibitors.